Maternal and foetal outcomes among 4118 women with HIV infection treated with lopinavir/ritonavir during pregnancy: Analysis of population-based surveillance data from the national study of HIV in pregnancy and childhood in the United Kingdom and Ireland

BMC Infectious Diseases

Volumn 16, Issue 1, 2016, Pages

  Tookey, Pat A ^a   Thorne, Claire ^a   van Wyk, Jean ^b   Norton, Michael ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ABBVIE INC   (United States)

Author keywords

Congenital abnormality; HIV; Lopinavir ritonavir; Pregnancy; Vertical transmission

Indexed keywords

LOPINAVIR PLUS RITONAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LOPINAVIR; RITONAVIR;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CONGENITAL DISORDER; DELIVERY; DRUG EFFICACY; DRUG EXPOSURE; FEMALE; FETUS; FETUS OUTCOME; GESTATIONAL AGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; IRELAND; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; PREGNANCY OUTCOME; PREVALENCE; TREATMENT DURATION; UNITED KINGDOM; VERTICAL TRANSMISSION; VIRUS INHIBITION; VIRUS LOAD; VIRUS TRANSMISSION; HEALTH SURVEY; HIV INFECTIONS; NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVENTION AND CONTROL; STATISTICS AND NUMERICAL DATA; TRANSMISSION;

ADULT; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; IRELAND; LOPINAVIR; POPULATION SURVEILLANCE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME; RITONAVIR; UNITED KINGDOM;

EID: 84959332596     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-016-1400-y     Document Type: Article

References (41)

1. Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002;29:484-94.
2. Duong T, Ades AE, Gibb DM, Tookey PA, Masters J. Vertical transmission rates for HIV in the British Isles: estimates based on surveillance data. BMJ. 1999;319:1227-9.
3. Townsend CL, Byrne L, Cortina-Borja M, Thorne C, de Ruiter A, Lyall H, et al. Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000-2011. AIDS. 2014;28:1049-57.
4. Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Trends in management and outcome of pregnancies in HIV-infected women in the UK and Ireland, 1990-2006. BJOG. 2008;115:1078-86.
5. Prieto LM, Gonzalez-Tome MI, Munoz E, Fernandez-Ibieta M, Soto B, Del Rosal T, et al. Low rates of mother-to-child transmission of HIV-1 and risk factors for infection in Spain: 2000-2007. Pediatr Infect Dis J. 2012;31:1053-8.
6. Warszawski J, Tubiana R, Le Chenadec J, Blanche S, Teglas JP, Dollfus C, et al. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French perinatal cohort. AIDS. 2008;22:289-99.
7. European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005;40:458-65.
8. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS. 2008;22:973-81.
9. Bailey H, Townsend CL, Semenenko I, Malyuta R, Cortina-Borja M, Thorne C. Impact of expanded access to combination antiretroviral therapy in pregnancy: results from a cohort study in Ukraine. Bull World Health Organ. 2013;91:491-500.
10. Li B, Zhao Q, Zhang X, Wu L, Chen T, Liang Z, et al. Effectiveness of a prevention of mother-to-child HIV transmission program in Guangdong province from 2007 to 2010. BMC Public Health. 2013;13:591.
11. Buchanan AM, Dow DE, Massambu CG, Nyombi B, Shayo A, Musoke R, et al. Progress in the prevention of mother to child transmission of HIV in three regions of Tanzania: a retrospective analysis. PLoS One. 2014;9:e88679.
12. Taylor GP, Clayden P, Dhar J, Gandhi K, Gilleece Y, Harding K, et al. British HIV association guidelines for the management of HIV infection in pregnant women 2012. HIV Med. 2012;13 Suppl 2:87-157.
13. World Health Organization. Programmatic update: use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. http://www.who.int/hiv/PMTCT_update.pdf. Accessed 2 Feb 2016.
14. World Health Organization. Use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. http://www.who.int/hiv/pub/mtct/advice/en/. Accessed 2 Feb 2016.
15. Aebi-Popp K, Mulcahy F, Glass TR, Rudin C, Martinez de Tejada B, Bertisch B, et al. Missed opportunities among HIV-positive women to control viral replication during pregnancy and to have a vaginal delivery. J Acquir Immune Defic Syndr. 2013;64:58-65.
16. Sibiude J, Mandelbrot L, Blanche S, Le Chenadec J, Boullag-Bonnet N, Faye A, et al. Association between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the French perinatal cohort study (ANRS CO1/CO11). PLoS Med. 2014;11:e1001635.
17. Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS. 2007;21:1019-26.
18. Powis KM, Kitch D, Ogwu A, Hughes MD, Lockman S, Leidner J, et al. Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis. 2011;204:506-14.
19. Newell ML, Bunders MJ. Safety of antiretroviral drugs in pregnancy and breastfeeding for mother and child. Curr Opin HIV AIDS. 2013;8:504-10.
20. Huntington SE, Thorne C, Bansi LK, Anderson J, Newell ML, Taylor GP, et al. Predictors of pregnancy and changes in pregnancy incidence among HIV-positive women accessing HIV clinical care. AIDS. 2013;27:95-103.
21. Schouten EJ, Jahn A, Midiani D, Makombe SD, Mnthambala A, Chirwa Z, et al. Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach. Lancet. 2011;378:282-4.
22. Cotter AM, Garcia AG, Duthely ML, Luke B, O'Sullivan MJ. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis. 2006;193:1195-201.
23. Kesho Bora Study Group, de Vincenzi I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (kesho Bora study): a randomised controlled trial. Lancet Infect Dis. 2011;11:171-80.
24. Dola CP, Khan R, DeNicola N, Amirgholami M, Benjamin T, Bhuiyan A, et al. Combination antiretroviral therapy with protease inhibitors in HIV-infected pregnancy. J Perinat Med. 2011;40:51-5.
25. Koss CA, Natureeba P, Plenty A, Luwedde F, Mwesigwa J, Ades V, et al. Risk factors for preterm birth among HIV-infected pregnant Ugandan women randomized to lopinavir/ritonavir-or efavirenz-based antiretroviral therapy. J Acquir Immune Defic Syndr. 2014;67:128-35.
26. Patel K, Shapiro DE, Brogly SB, Livingston EG, Stek AM, Bardeguez AD, et al. Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy. J Infect Dis. 2010;201:1035-44.
27. Ravizza M, Martinelli P, Bucceri A, Fiore S, Alberico S, Tamburrini E, et al. Treatment with protease inhibitors and coinfection with hepatitis C virus are independent predictors of preterm delivery in HIV-infected pregnant women. J Infect Dis. 2007;195:913-4. author reply 916-7.
28. Watts DH, Williams PL, Kacanek D, Griner R, Rich K, Hazra R, et al. Pediatric HIV/AIDS cohort study: combination antiretroviral use and preterm birth. J Infect Dis. 2013;207:612-21.
29. Pasley MV, Martinez M, Hermes A, d'Amico R, Nilius A. Safety and efficacy of lopinavir/ritonavir during pregnancy: a systematic review. AIDS Rev. 2013;15:38-48.
30. Bailey H, Townsend CL, Cortina-Borja M, Thorne C. European collaborative study in EuroCoord: improvements in virological control among women conceiving on combination antiretroviral therapy in western Europe. AIDS. 2013;27:2312-5.
31. Hawkins D, Blott M, Clayden P, de Ruiter A, Foster G, Gilling-Smith C, et al. Guidelines for the management of HIV infection in pregnant women and the prevention of mother-to-child transmission of HIV. HIV Med. 2005;6 Suppl 2:107-48.
32. Peters H, Tookey P. Variation in mode of delivery for HIV-positive women in UK & Irish hospitals, 2008-2013. HIV Med. 2014;15:2.
33. Briand N, Jasseron C, Sibiude J, Azria E, Pollet J, Hammou Y, et al. Cesarean section for HIV-infected women in the combination antiretroviral therapies era, 2000-2010. Am J Obstet Gynecol. 2013;209:335. e331-5, e312.
34. Townsend CL, Willey BA, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990-2007. AIDS. 2009;23:519-24.
35. British Isles Network of Congenital Anomaly Registers: Congenital Anomaly Statistics 2011 England and Wales. http://www.binocar.org/Publications/Reports. Accessed 2 Feb 2016.
36. Antiretroviral Pregnancy Registry Steering Committee: Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 January 2014. http://www.apregistry.com/forms/interim_report.pdf. Accessed 18 Jul 2014.
37. Reitter A, Stucker AU, Linde R, Konigs C, Knecht G, Herrmann E, et al. Pregnancy complications in HIV-positive women: 11-year data from the Frankfurt HIV cohort. HIV Med. 2014;15:525-36.
38. Office for National Statistics: Births in England and Wales, 2013. http://www.ons.gov.uk/ons/dcp171778_371129.pdf. Accessed 2 Feb 2016.
39. Confidential Enquiry into Maternal and Child Health. Stillbirth, Neonatal and Post-neonatal Mortality 2000-2003, England, Wales and Northern Ireland. http://www.lho.org.uk/Download/Public/9713/1/CEMACHPerinatalMortalityReportApril2005_4.pdf. Accessed 2 Feb 2016.
40. World Health Organization. European Action Plan for HIV/AIDS 2012-2015. http://www.euro.who.int/en/health-topics/communicable-diseases/sexually-transmitted-infections/publications2/2011/european-action-plan-for-hivaids-20122015. Accessed 2 Feb 2016.
41. Kissin DM, Mandel MG, Akatova N, Belyakov NA, Rakhmanova AG, Voronin EE, et al. Five-year trends in epidemiology and prevention of mother-to-child HIV transmission, St. Petersburg, Russia: results from perinatal HIV surveillance. BMC Infect Dis. 2011;11:292.